Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR142 | Q7Z601 | 8/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982479 | 0.74 | ACACB (0.46) | NPC1RAB9ASMN1; SMN2CTSKTDP1 | |
| SCHEMBL105278 | 0.70 | SLC6A3 (0.39) | NPC1RAB9ASMN1; SMN2GPR142CTSK | |
| SCHEMBL5442013 | 0.69 | CYP2C19 (0.42) | NPC1RAB9ACYP3A4 | |
| SCHEMBL9481 | 0.68 | CTSK (0.43) | NPC1RAB9ASMN1; SMN2CTSKTDP1 | |
| SCHEMBL16887640 | 0.67 | RAB9A (0.40) | NPC1RAB9ASMN1; SMN2TDP1SLC6A3 | |
| SCHEMBL28195168 | 0.66 | CTSK (0.44) | NPC1RAB9ASMN1; SMN2CTSKTDP1 | |
| SCHEMBL7395331 | 0.66 | MAPK1 (0.52) | SMN1; SMN2CTSK | |
| SCHEMBL6194153 | 0.66 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2GPR142CTSK | |
| SCHEMBL6194155 | 0.66 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2GPR142CTSK | |
| SCHEMBL20509000 | 0.65 | TDP1 (0.43) | NPC1RAB9ASMN1; SMN2TDP1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | NPC1 593/4885RAB9A 874/4885SMN1; SMN2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.